iconstar paper   HIV Articles  
Back grey arrow rt.gif
New HIV Drugs Include the LAI CAB+RPV & Lenacapavir, Merck restart of studying Islatravir, plus below I have included recent new study results from these therapies and Fostemsavir, the 2 drug combination of Dolutegravir/3TC, and 5-year update of Biktarvy (Bictegravir/TAF/3TC)
  .....the use of long-acting injectable CAB/RPV has been increasing so below are just presented new study results from the recent Glasgow conference on ways in which to optimize its use, patient satisfaction, and ways to address barriers to its use in the clinic
Glasgow: Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/28/22)
Glasgow: Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study) - (10/27/22)
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection https://www.natap.org/2022/HIV/092022_01.htm
Glasgow: Virologic Failure Rate 1.4% in 3 Years of CAB + RPV Phase 3 Trials: Pre-existing RPV Resistance, CAB and RPV Troughs Predict Failure - (11/01/22)
Glasgow: Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Black and Asian Participants From TANGO and SALSA: Pooled 48-Week Data Analyzed by Race - (11/17/22)
Glasgow: Durable Efficacy of Switching From a 3-/4-Drug Tenofovir Alafenamide (TAF)-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine (DTG/3TC) in the TANGO Study Through Week 196 - (10/28/22)
Glasgow: High Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Naive Adults With HIV-1 and High Baseline Viral Load (VL): 48-Week Subgroup Analyses of the GEMINI-1/-2 and STAT Trials - (10/28/22)
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges (PrEP)- (11/14/22)
Glasgow: Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study - (11/01/22)
Glasgow: A Multivariate Analysis of the Phase 3 BRIGHTE Trial, Through Week 24, to Identify Predictors of Virologic Response to Fostemsavir in Heavily Treatment-Experienced People Living With HIV - (10/31/22)
Glasgow: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study - (10/31/22)
Glasgow: Patient-Reported Outcomes After 152 Weeks of HIV Maintenance Therapy With Long-Acting Cabotegravir + Rilpivirine in the Phase 3b ATLAS-2M Study - (10/31/22)
Glasgow: 6-Month Outcomes of Every 2 Months Long-Acting Cabotegravir and Rilpivirine in a Real-World Setting - Effectiveness, Adherence to Injections, and Patient- Reported Outcomes of People Living With HIV in the German CARLOS Cohort - (10/28/22)
Glasgow: Overcoming Barriers and Achieving Optimal Implementation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA): Staff Study Participant (SSP) Results From the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/27/22)

  iconpaperstack View Older Articles   Back to Top   www.natap.org